8-K current report · filed Nov 12, 2026

Alkermes plc. (ALKS) 8-K Current Report: November 12, 2026

Item 1.01ALKS overview

Short answer

Alkermes plc. (ALKS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Patent litigation with Teva resolved for all LYBALVI dosage strengths through a settlement and license agreement.

Alkermes plc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Patent litigation with Teva resolved for all LYBALVI dosage strengths through a settlement and license agreement
  • Teva’s U.S. generic entry permitted beginning November 12, 2039, or May 12, 2040 with pediatric exclusivity
  • Earlier entry remains possible under certain settlement conditions, creating long-term generic competition risk
  • Pending New Jersey infringement proceedings dismissed with prejudice, subject to FTC and DOJ review

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Alkermes plc. 8-K filings

Get the next ALKS 8-K as it lands

Follow ALKS for push alerts, or ask the research agent what this filing means.